Vitiligo showdown: new drug vs. old combo in Head-to-Head trial
NCT ID NCT07368673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a newer cream (ruxolitinib) works better alone or when combined with two older creams (tacrolimus and corticosteroids) for vitiligo. 120 adults with limited vitiligo (less than 10% of body affected) were split into three groups and treated for 24 weeks. The goal was to see which approach restores more skin color safely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dow University of health sciences
Karachi, Sindh, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New ointment aims to restore skin color in vitiligo
- Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
- New vitiligo registry aims to uncover disease trends in 2,500 patients
- Scientists probe immune secrets of four skin diseases
- Lamp vs laser: which light works best for vitiligo?
- New shot plus light therapy aims to restore skin color in vitiligo